Evidence map›Paper›PMID 35667065›Full record

Trial reportAnnals of internal medicine2022

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.

Matthew G Johnson, Amy Puenpatom, Pablo Andrés Moncada, Lesley Burgess, Elizabeth R Duke, Norio Ohmagari, Timo Wolf, Matteo Bassetti, Sanjay Bhagani, Jade Ghosn and 6 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04575597 (A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.), which is not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04575597 phase2 / phase3completednot on this map

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2020 to 2022Enrolled1,735ConditionsCoronavirus Disease (COVID-19)ArmsMolnupiravir, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  6. Trial
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 8 countries.

Matthew G JohnsonMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Amy PuenpatomMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Pablo Andrés MoncadaFundacion Valle del Lili, Cali, Colombia (P.A.M.).
Lesley BurgessTREAD Research, Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and Stellenbosch University, Parow, South Africa (L.B.).ORCID 0000-0002-4457-0596
Elizabeth R DukeFred Hutchinson Cancer Research Center, Seattle, Washington (E.R.D.).ORCID 0000-0002-3348-9039
Norio OhmagariNational Center for Global Health and Medicine, Tokyo, Japan (N.O.).ORCID 0000-0002-4622-8970
Timo WolfUniversitätsklinikum Frankfurt, Frankfurt am Main, Germany (T.W.).ORCID 0000-0002-3819-9540
Matteo BassettiIRCCS Ospedale Policlinico San Martino, and Department of Health Sciences, University of Genoa, Genova, Italy (M.B.).ORCID 0000-0002-0145-9740
Sanjay BhaganiRoyal Free London NHS Foundation Trust, London, United Kingdom (S.B.).
Jade GhosnAP-HP. Nord, Hôpital Bichat - Claude Bernard, and Université Paris Cité, INSERM UMR 1137 IAME, Paris, France (J.G.).ORCID 0000-0003-2914-959X
Ying ZhangMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Hong WanMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).ORCID 0000-0003-0679-9565
Angela Williams-DiazMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Michelle L BrownMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Amanda PaschkeMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Carisa De AndaMerck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.).
Merck & Co., Inc., Rahway, NJ, USA (United States) · USFred Hutch Cancer Center · USFundación Valle del Lili · COGoethe University Frankfurt · DENational Center for Global Health and Medicine · JPOspedale Policlinico San Martino · ITRoyal Free London NHS Foundation Trust · GBStellenbosch University · ZAUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease.

objectiveTo identify other potential clinical benefits of molnupiravir versus placebo.

designSecondary analysis of the randomized, double-blind, placebo-controlled phase 3 component of MOVe-OUT. (ClinicalTrials.gov: NCT04575597).

setting107 sites globally.

participants1433 nonhospitalized adults aged 18 years or older with mild to moderate COVID-19.

interventionMolnupiravir, 800 mg, or placebo every 12 hours for 5 days. MEASUREMENTS: Changes from baseline in C-reactive protein (CRP) concentration and oxygen saturation (Spo

resultsParticipants receiving molnupiravir showed faster normalization of CRP and Spo LIMITATIONS: Some analyses were performed post hoc. Longer-term benefits of molnupiravir therapy were not evaluated. Participants were not immunized against SARS-CoV-2.

conclusionThe findings suggest there are additional important clinical benefits of molnupiravir beyond reduction in hospitalization or death. PRIMARY FUNDING SOURCE: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Indexed as

COVID-19AdultBiomarkersCytidineDouble-Blind MethodHumansHydroxylaminesRespiration, ArtificialSARS-CoV-2Treatment OutcomeBiomarkersCytidineHydroxylaminesmolnupiravir

Identifiers

PMID35667065
PMCPMC9186515
OpenAlexW4281700140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.